Pamela Spicer (@Datamonitor_PS) header
Pamela Spicer (@Datamonitor_PS) profile picture

Analyst | Autoimmune & Inflammation | CNS | Views & opinions expressed are strictly my own

Joined September 2014
US #depression drug market growth expected, but familiar brand names projected to lose market share pharmaintelligence.informa.c…
3
2
Anti-IL-17 follows anti-TNF in late phase trials for axial #spondyloarthritis. Read more by @CitelineLauraR https://teapawt.org/t.co/fn8ZJ9ZhvC
Register for today’s free webinar looking at unapproved drug activity and trials supporting market/label expansion: https://teapawt.org/t.co/jHrft8TZKj
1
Starting now! Hear how to mitigate the risk of selecting a non-enrolling site for your clinical trial: https://teapawt.org/t.co/86kU9HizlV
Excellent paper by @CitelineLauraR on #biosimilar clinical trials. Free: https://teapawt.org/t.co/SJgiRnbtY3
6
1
Join today's R&D webinar to see where the #pharma industry maximizing value Register for free: https://teapawt.org/t.co/SftvVdTE7n
In honor of World Autoimmune Arthritis Day and #ClinicalTrialsDay on May 20th, #Citeline shows rheumatoid #arthritis trial locations #WAAD17
1
Trialtrove shows 467 planned or ongoing #asthma clinical trials on #WorldAsthmaDay. #AsthmaAwarenessMonth
Prexton CEO interviewed by @ScripLucie regarding novel Parkinson's therapy foliglurax, now prepping Phase 2 study youtu.be/CkdN3xRcUI8
3
2